scPharmaceuticals Inc
NASDAQ:SCPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Infrastrutture Wireless Italiane SpA
MIL:INW
|
IT |
|
T
|
Toronto-Dominion Bank
XBER:TDB
|
CA |
|
S
|
Sea Ltd
SWB:931
|
SG |
|
G
|
Global PMX Co Ltd
TWSE:4551
|
TW |
|
Ocean Outdoor Ltd
LSE:OOUT
|
VG |
|
Shenzhen Kedali Industry Co Ltd
SZSE:002850
|
CN |
|
S
|
Shizuki Electric Co Inc
TSE:6994
|
JP |
|
Walsin Lihwa Corp
TWSE:1605
|
TW |
|
S Enjoy Service Group Co Ltd
HKEX:1755
|
CN |
|
Allcargo Logistics Ltd
NSE:ALLCARGO
|
IN |
|
S
|
Spotify Technology SA
SWB:639
|
LU |
|
Sato Foods Co Ltd
TSE:2923
|
JP |
|
M
|
MGB Bhd
KLSE:MGB
|
MY |
|
Charisma Energy Services Ltd
SGX:5QT
|
SG |
|
T
|
Tecnotree Oyj
OMXH:TEM1V
|
FI |
|
Cloetta AB
STO:CLA B
|
SE |
|
S
|
Suraj Estate Developers Ltd
NSE:SURAJEST
|
IN |
|
N
|
Nippon Paper Industries Co Ltd
TSE:3863
|
JP |
|
TRE Holdings Corp
TSE:9247
|
JP |
scPharmaceuticals Inc
Total Liabilities
scPharmaceuticals Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
scPharmaceuticals Inc
NASDAQ:SCPH
|
Total Liabilities
$101.6m
|
CAGR 3-Years
76%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Liabilities
$117.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Liabilities
$71.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
15%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Liabilities
$121.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Liabilities
$84.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Liabilities
$85.9B
|
CAGR 3-Years
30%
|
CAGR 5-Years
16%
|
CAGR 10-Years
15%
|
|
scPharmaceuticals Inc
Glance View
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2017-11-17. The firm is focused on exploring, developing and commercializing products that expand and advance the outpatient care of acute conditions, including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for treatment of congestion in patients with heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Its area of focus is congestion in heart failure and outpatient parenteral antimicrobial therapy (OPAT). Its pipeline programs include FUROSCIX, scCeftriaxone and scCarbapenem. Its FUROSCIX On-Body Infusor is a drug-device combination product consisting of FUROSCIX. The firm's wholly owned subsidiary is scPharmaceuticals Securities Corporation.
See Also
What is scPharmaceuticals Inc's Total Liabilities?
Total Liabilities
101.6m
USD
Based on the financial report for Jun 30, 2025, scPharmaceuticals Inc's Total Liabilities amounts to 101.6m USD.
What is scPharmaceuticals Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
31%
Over the last year, the Total Liabilities growth was 81%. The average annual Total Liabilities growth rates for scPharmaceuticals Inc have been 76% over the past three years , 31% over the past five years .
